Hyloris Pharmaceuticals SA
XBRU:HYL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hyloris Pharmaceuticals SA
XBRU:HYL
|
BE |
Balance Sheet
Balance Sheet Decomposition
Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA
Balance Sheet
Hyloris Pharmaceuticals SA
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
0
|
3
|
0
|
64
|
50
|
43
|
30
|
24
|
14
|
|
| Cash Equivalents |
0
|
3
|
0
|
64
|
50
|
43
|
30
|
24
|
14
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
1
|
10
|
0
|
1
|
0
|
|
| Total Receivables |
0
|
1
|
0
|
0
|
2
|
4
|
4
|
5
|
6
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
2
|
4
|
4
|
5
|
5
|
|
| Other Receivables |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
3
|
2
|
1
|
3
|
1
|
0
|
0
|
|
| Total Current Assets |
1
|
4
|
4
|
67
|
54
|
50
|
35
|
30
|
20
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
2
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
|
| Intangible Assets |
4
|
4
|
2
|
2
|
3
|
4
|
4
|
4
|
6
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
2
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
5
|
5
|
5
|
4
|
4
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
2
|
1
|
2
|
0
|
0
|
|
| Total Assets |
4
N/A
|
8
+82%
|
6
-25%
|
69
+1 056%
|
63
-8%
|
61
-4%
|
48
-21%
|
41
-13%
|
33
-19%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
2
|
2
|
3
|
2
|
3
|
2
|
3
|
3
|
5
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
1
|
13
|
0
|
12
|
3
|
3
|
3
|
0
|
|
| Total Current Liabilities |
2
|
3
|
16
|
2
|
15
|
6
|
7
|
7
|
5
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
1
|
|
| Minority Interest |
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
7
|
9
|
0
|
8
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
9
N/A
|
10
+18%
|
16
+59%
|
10
-37%
|
15
+52%
|
7
-56%
|
9
+26%
|
9
+7%
|
7
-25%
|
|
| Equity | ||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
23
|
26
|
34
|
45
|
56
|
63
|
78
|
85
|
91
|
|
| Additional Paid In Capital |
18
|
24
|
24
|
104
|
104
|
122
|
122
|
122
|
122
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
4
|
4
|
4
|
4
|
|
| Total Equity |
4
N/A
|
2
+48%
|
10
-354%
|
59
N/A
|
48
-19%
|
54
+12%
|
39
-28%
|
32
-18%
|
26
-18%
|
|
| Total Liabilities & Equity |
4
N/A
|
8
+82%
|
6
-25%
|
69
+1 056%
|
63
-8%
|
61
-4%
|
48
-21%
|
41
-13%
|
33
-19%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
18
|
18
|
18
|
26
|
26
|
28
|
28
|
28
|
28
|
|